LUZU® STRENGTH
(luliconazole) Cream, 1%

CLINICAL CASE

INTERDIGITAL TINEA PEDIS
Caused by T. rubrum in a 94-year-old male patient

Once-daily dosing:\: Apply once daily for 2 weeks for tinea pedis
- Efficacy seen at 4 weeks post-treatment

BEFORE

AFTER

BASELINE
Erythema and scaling*

4 WEEKS POST-TREATMENT
Complete clearance*

Photos from a clinical case courtesy of Brant McCartan, DPM.

*These unretouched photos represent actual clinical experience. Individual results may vary.

Study Design: Two randomized, double-blind, vehicle-controlled, multicenter trials in 423 subjects with a clinical and culture-confirmed diagnosis of interdigital tinea pedis. Signs and symptoms of interdigital tinea pedis (pruritus, erythema, and scaling), KOH exam, and dermatophyte culture were assessed at baseline, end of treatment (Day 14), and 2 and 4 weeks post-treatment. Complete clearance (mycological cure, shown by negative KOH and negative fungal culture, and clinical cure, shown by the absence of pruritus, erythema, and scaling) at 4 weeks post-treatment was the primary efficacy endpoint.

Clinical studies show that in Study 1, 26% of patients treated with LUZU vs 2% of patients treated with vehicle achieved complete clearance. In Study 2, 14% of patients treated with LUZU vs 3% of patients treated with vehicle achieved complete clearance.\:

Indications and Usage

LUZU (luliconazole) Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum in patients 18 years of age and older.

Please see Important Safety Information on reverse.
LUZU® stops fungus with the simplicity of once-daily dosing.

Proven power to clear interdigital tinea pedis due to *T. rubrum* and *E. floccosum*:

- LUZU has the strength to clear your patients’ fungus and relieve signs and symptoms of pruritus, erythema, and scaling

**Once-daily dosing**: 

- Apply once daily for 2 weeks for tinea pedis
  - Efficacy seen at 4 weeks post-treatment

**Important Safety Information**

LUZU is indicated for topical use only and is not indicated for ophthalmic, oral or intravaginal use.

LUZU should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Caution should be exercised when LUZU is prescribed for nursing mothers.

The most common adverse reactions in clinical trials were application site reactions, which occurred in less than 1% of subjects in both LUZU and vehicle arms. Most adverse reactions were mild in severity.

Please see accompanying Full Prescribing Information or visit LuzuRx.com.